A noninvasive bimodal sensory device that delivers combined stimulation of sound and electrical stimulation of the tongue reduces symptoms associated with ringing in the ears, or tinnitus, a study shows.
Remote electrical neurostimulation delivered via a device worn around the upper arm provides consistent relief in acute migraine patients treated in a real-world clinical setting, reducing the use of medications while having a favourable safety profile, as shown in a study.
The 0.5-mg dose of fingolimod has a superior benefit-risk profile over the 0.25-mg dose, and was superior to glatiramer acetate (GA) – a widely used, effective drug for multiple sclerosis (MS), for treating adults with relapsing or remitting forms of MS (RRMS), the ASSESS study has shown.
Endovascular therapy, especially when performed immediately after stroke onset, saves patients and the healthcare system money by improving functional outcome and reducing morbidity as compared with less expensive alternative treatments, as shown in a Singapore study.
Treatment with the anti-CD20 monoclonal antibody ofatumumab reduced relapse rate in patients with relapsing multiple sclerosis (MS) compared with the pyrimidine synthesis inhibitor teriflunomide, according to results of the phase III ASCLEPIOS I and II* trials.
A new combination product (AXS-07), which consists of the triptan rizatriptan and the NSAID* meloxicam, led to rapid and sustained pain relief than treatment with either component alone or placebo in patients with a history of inadequate response to prior acute migraine treatment, according to data from the MOMENTUM study released during the AAN 2020 Meeting.
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.